In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa: Results from a Multicenter Study in China, 2017.

In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa: Results from a Multicenter Study in China, 2017. Antimicrob Agents Chemother. 2019 Jan 07;: Authors: Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F Abstract The in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam and comparators were determined for 1,774 isolates of Enterobacteriaceae and 524 isolates of Pseudomonas aeruginosa collected by 30 medical centers across China in 2017. Antimicrobial susceptibility testing was performed by CLSI broth microdilution. And bla KPC and bla NDM were detected by PCR for all carbapenem-resistant Enterobacteriaceae (CRE). Ceftazidime-avibactam demonstrated potent activity against almost all Enterobacteriaceae (94.6% susceptibility; MIC50≤0.25 mg/L; MIC90, ≤0.25- >32 mg/L) and good against P. aeruginosa (86.5% susceptibility; MIC50/90, 2/16 mg/L). bla KPC-2 was positive among 50.8% (189/372) of the CRE, mainly existed in ceftazidime-avibactam susceptible K. pneumoniae (92.1%, 174/189). bla NDM were positive among 17.7% (66/372) of the CRE and mainly existed in strains resistant to ceftazidime-avibactam (71.7%, 66/92). Ceftolozane-tazobactam showed good in vitro activity against E. coli and P. mirabilis (MIC50/90, ≤0.5/2; 90.5 and 93.8% susceptibility), and susceptibility of K. pneumoniae (MIC50/90, 2/>64 mg/L) and P. aeruginosa...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research